共 50 条
- [31] A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF SYSTEMIC THERAPY VERSUS STANDARD OF CARE INTRAVESICAL TREATMENT (BCG) IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTSJOURNAL OF UROLOGY, 2024, 211 (05): : E991 - E992Rivera-Marquez, GenesisWalter, BeatrizDolan, RebeccaBelfield, SoniaValera, Vladimir A.
- [32] Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AMLJournal of Hematology & Oncology, 14Jorge E. CortesTara L. LinGeoffrey L. UyRobert J. RyanStefan FaderlJeffrey E. Lancet
- [33] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Cella, DavidHackshaw, Michelle D.Vondeling, Gerard T.Bennett, LeeGarbinsky, DianaSaito, KakuSugihara, MasahiroBang, Yung-JueYamaguchi, KenseiShitara, Kohei
- [34] Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus ImatinibCANCER MEDICINE, 2025, 14 (07):Ashaye, AjibadeShi, LingAldoss, IbrahimMontesinos, PauVachhani, PankitRocha, VandersonPapayannidis, CristinaLeonard, Jessica T.Baer, Maria R.Ribera, Jose-MariaMcCloskey, JamesWang, JianxiangRane, DeepaliGuo, Shien
- [35] Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab plus rivoceranib (cam plus rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310ANNALS OF ONCOLOGY, 2024, 35 : S663 - S663Moon, A.Raphael, N.Chan, S. L.Kaseb, A. O.Jang, S. H.Meng, X.Cheng, A-L.Qin, S.Vogel, A.
- [36] Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AMLJOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)Cortes, Jorge E.Lin, Tara L.Uy, Geoffrey L.Ryan, Robert J.Faderl, StefanLancet, Jeffrey E.
- [37] A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis comparing lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in HER2+patients.CANCER RESEARCH, 2009, 69 (02) : 277S - 277SSherrill, B.Dileo, A.Amonkar, M.Koehler, M.Arbushites, M.
- [38] 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' (vol 94, pg 115, 2018)EUROPEAN JOURNAL OF CANCER, 2018, 103 : 287 - 287Choueiri, Toni K.Hessel, ColinHalabi, SusanSanford, BenMichaelson, M. DrorHahn, OlwenWalsh, MegharaOlencki, ThomasPicus, JoelSmall, Eric J.Dakhil, ShakerFeldman, Darren R.Mangeshkar, MilanScheffold, ChristianGeorge, DanielMorris, Michael J.
- [39] A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N plus I) or nivolumab plus chemotherapy (N plus CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 251 - 251Chau, IanBridgewater, John A.Wyrwicz, LucjanGreenwood, MikeBlum, Steven I.Moreno-Koehler, AlejandroWorthy, GillTaylor, FionaDavis, CatherineChen, Clara
- [40] A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N plus CT) or nivolumab plus ipilimumab (N plus I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648ANNALS OF ONCOLOGY, 2024, 35 : S162 - S162Chau, I.Bridgewater, J. A.Wyrwicz, L. S.Greenwood, M.Blum, S. I.Moreno-Koehler, A.Martin, E.Taylor, F.Davis, C.Singh, P.